Zhejiang Yatai Pharmaceutical (002370.SZ): The application for the consistency evaluation of Deltaparin hydrochloride tablets was not approved.

Zhejiang Yatai Pharmaceutical (002370.SZ) announced that the company recently received a notification from the National Medical Products Administration stating that the application for the consistency evaluation of Diltiazem Hydrochloride tablets was not approved. Diltiazem Hydrochloride tablets are used for the treatment of angina pectoris and mild to moderate hypertension. According to the notification, the reason for the disapproval is that the bioequivalence study submitted does not support the conclusion of bioequivalence.